MLTX vs. MRNA, VTRS, QGEN, BPMC, ROIV, RVMD, VRNA, BBIO, ELAN, and GRFS
Should you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Blueprint Medicines (BPMC), Roivant Sciences (ROIV), Revolution Medicines (RVMD), Verona Pharma (VRNA), BridgeBio Pharma (BBIO), Elanco Animal Health (ELAN), and Grifols (GRFS). These companies are all part of the "pharmaceutical products" industry.
MoonLake Immunotherapeutics vs. Its Competitors
MoonLake Immunotherapeutics (NASDAQ:MLTX) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, valuation, risk, profitability, dividends, earnings, analyst recommendations, media sentiment and community ranking.
MoonLake Immunotherapeutics presently has a consensus price target of $78.71, suggesting a potential upside of 83.18%. Moderna has a consensus price target of $46.61, suggesting a potential upside of 71.62%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe MoonLake Immunotherapeutics is more favorable than Moderna.
In the previous week, Moderna had 6 more articles in the media than MoonLake Immunotherapeutics. MarketBeat recorded 17 mentions for Moderna and 11 mentions for MoonLake Immunotherapeutics. MoonLake Immunotherapeutics' average media sentiment score of 0.76 beat Moderna's score of 0.51 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media.
MoonLake Immunotherapeutics has a net margin of 0.00% compared to Moderna's net margin of -110.04%. MoonLake Immunotherapeutics' return on equity of -15.54% beat Moderna's return on equity.
93.8% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 75.3% of Moderna shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by company insiders. Comparatively, 11.0% of Moderna shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
MoonLake Immunotherapeutics has higher earnings, but lower revenue than Moderna. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.
Moderna received 143 more outperform votes than MoonLake Immunotherapeutics when rated by MarketBeat users. However, 82.02% of users gave MoonLake Immunotherapeutics an outperform vote while only 53.07% of users gave Moderna an outperform vote.
MoonLake Immunotherapeutics has a beta of 1.23, meaning that its share price is 23% more volatile than the S&P 500. Comparatively, Moderna has a beta of 1.86, meaning that its share price is 86% more volatile than the S&P 500.
Summary
MoonLake Immunotherapeutics beats Moderna on 12 of the 18 factors compared between the two stocks.
Get MoonLake Immunotherapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MoonLake Immunotherapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:MLTX) was last updated on 6/12/2025 by MarketBeat.com Staff
Buy MLTX Stock Free MLTX Stock Alerts